article Open AccessTop 1% cited

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

New England Journal of Medicine · 2012 · Vol. 366(26) · pp. 2455–2465

Julie R. Brahmer✉(Johns Hopkins University)Scott S. Tykodi(Fred Hutch Cancer Center)Laura Q.M. Chow(Seattle Cancer Care Alliance)Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center)Suzanne L. Topalian(Johns Hopkins University)Patrick Hwu(The University of Texas MD Anderson Cancer Center)Charles G. Drake(Johns Hopkins University)Luis H. Camacho(St. Luke's Episcopal Hospital)John Kauh(Emory University)Kunle Odunsi(Roswell Park Comprehensive Cancer Center)Henry C. Pitot(Mayo Clinic)Omid Hamid(Angeles Clinic and Research Institute)Shailender Bhatia(Fred Hutch Cancer Center)Renato Martins(Fred Hutch Cancer Center)Keith D. Eaton(Fred Hutch Cancer Center)Shuming Chen(Sidney Kimmel Comprehensive Cancer Center)Theresa M. Salay(Johns Hopkins University)Suresh Alaparthy(Bristol-Myers Squibb (United States))Joseph F. Grosso(Bristol-Myers Squibb (United States))Alan J. Korman(Bristol-Myers Squibb (Germany))Susan Parker(Bristol-Myers Squibb (United States))Shruti Agrawal(Bristol-Myers Squibb (United States))S. Goldberg(Bristol-Myers Squibb (United States))Drew M. Pardoll(Johns Hopkins University)Ashok Gupta(Bristol-Myers Squibb (United States))Jon M. Wigginton(Bristol-Myers Squibb (United States))

View via DOI Full-text PDF

Abstract

Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks) in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00729664.).

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune ResponsesBlockadeImmune systemPD-L1MedicineAntibodyIn vitroCancerCancer researchReceptorImmune checkpoint

MeSH terms

NivolumabAdultAntibodies, MonoclonalAntineoplastic AgentsBreast NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellDose-Response Relationship, DrugFemaleHumansMaleMelanomaNeoplasmsOvarian NeoplasmsPancreatic Neoplasms

Citations

7,941

FWCI

292.10

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

<scp>LAG</scp>3 (<scp>CD</scp>223) as a cancer immunotherapy target